信立泰：SAL0137开展治疗脂蛋白（a）增高的临床试验

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein (a) levels [1] Group 1 - The drug SAL0137 is developed independently by the company [1] - The approval allows the company to initiate clinical trials for SAL0137 [1] - The focus of the clinical trial is on treating elevated lipoprotein (a) levels, which is a significant health concern [1]